Moderna Vaccine: Effective Shield Against Hospitalization

The Moderna COVID-19 vaccine has been found to be highly effective in preventing hospitalization. A CDC-led study from 2021 found that the Moderna vaccine was 93% effective in preventing hospitalization, compared to 88% for the Pfizer vaccine and 71% for the Johnson & Johnson vaccine. Another study from March 2025 estimated the effectiveness of the current Moderna vaccine to be 53% against COVID-19-related hospitalization. Overall, the Moderna vaccine has been shown to provide substantial protection against hospitalization, and it is considered one of the most effective vaccines available.

Moderna vaccine 93% effective against COVID-19 hospitalisation

A 2021 US Centers for Disease Control and Prevention (CDC)-led study found that the Moderna vaccine was 93% effective against COVID-19 hospitalisation. The study involved 3,689 adults aged 18 and older who had been hospitalised at 21 hospitals across 18 states between March 11, 2021, and August 15, 2021. The participants were not all hospitalised due to COVID-19.

The Moderna vaccine was found to be the most effective vaccine against COVID-19 hospitalisation when compared to the Pfizer-BioNTech and Johnson & Johnson vaccines, which were found to be 88% and 71% effective, respectively. The CDC report concluded that "all FDA-approved or authorised COVID-19 vaccines provide substantial protection against COVID-19 hospitalisation".

The Moderna vaccine's effectiveness against COVID-19 hospitalisation was also found to be long-lasting. While the effectiveness of the Pfizer vaccine fell to 77% beyond 120 days after inoculation, Moderna maintained its 93% effectiveness for at least four months after the second dose. After this period, its effectiveness dropped slightly to 92%.

The CDC study also found that the Moderna vaccine had higher antibody levels after vaccination than the Pfizer and Johnson & Johnson vaccines. Researchers speculated that the differences in effectiveness could be due to higher mRNA content in the Moderna vaccine or differences in the timing between doses.

Moderna vaccine has higher antibody levels than Pfizer

The Moderna vaccine has been found to be more effective than the Pfizer vaccine in preventing COVID-19-related hospitalizations. A CDC study involving over 3,600 adults hospitalized across 18 states found that the Moderna vaccine had a 93% effectiveness rate in preventing hospitalizations, while the Pfizer vaccine had an 88% effectiveness rate.

The Moderna vaccine was introduced in December 2020 and has since been updated to target new virus variants. It uses mRNA technology, which stimulates the immune system to produce antibodies and T-cell immune responses. Similarly, the Pfizer vaccine, which was also introduced in December 2020, has been updated to target new virus variants, including the Omicron strain and its iterations.

A recent study published by Moderna found that their combination mRNA shot for COVID-19 and the flu generated a stronger immune response than standalone shots in individuals aged 50 and older. This combination vaccine produced higher antibody levels in the blood, suggesting increased protection against COVID-19 and multiple influenza strains.

While the Moderna vaccine has demonstrated higher effectiveness against hospitalization, both the Moderna and Pfizer vaccines have been critical in preventing severe COVID-19 illness and reducing the risk of hospitalization. The CDC has emphasized that all FDA-approved or authorized COVID-19 vaccines provide substantial protection against hospitalization due to COVID-19.

Moderna's effectiveness against hospitalisation maintained beyond 120 days

A three-dose Moderna vaccine regimen was found to be more effective against COVID-19-related hospitalisation than the Pfizer regimen at 14 to 120 days post-vaccination. The effectiveness of the Moderna vaccine was found to be 77.2% at 14 to 60 days, 42.1% at 61 to 90 days, 34.8% at 91 to 120 days, and 39% beyond 120 days.

The Centers for Disease Control and Prevention (CDC) in the US found the Moderna vaccine to be the most effective against Covid-19 hospitalisation, with 93% effectiveness, while the Pfizer-BioNTech and Johnson & Johnson vaccines were found to be 88% and 71% effective, respectively. The study involved more than 3,600 adults who were hospitalised at 21 hospitals across 18 states between March and August.

Another study, which has not yet been peer-reviewed, evaluated the effectiveness of Moderna's updated vaccine targeting the KP.2 variant. The study found that the vaccine was 53% effective against COVID-19-related hospitalisation and 39% protective against medically attended COVID-19 over a median follow-up period of 57 days.

Moderna's vaccine effectiveness against hospitalisation is 53%

A recent preprint study has estimated that the Moderna COVID-19 vaccine is 53% effective against COVID-19-related hospitalisation. The study, which has not yet been peer-reviewed, evaluated the effectiveness of Moderna's updated vaccine in preventing hospitalisations. The results indicate that the Moderna vaccine provides incremental protection against hospitalisation from the circulating variants.

The Moderna vaccine's effectiveness against hospitalisation is a critical aspect of COVID-19 management. The study compared the outcomes of vaccine recipients with those who did not receive any 2024-25 COVID vaccine. This matched cohort study used electronic health records to determine vaccinations and follow-up data. The findings suggest that the Moderna vaccine offers a significant level of protection against severe illness requiring hospitalisation.

While the study provides valuable insights, it is important to interpret the results in context. The Moderna vaccine's effectiveness against hospitalisation may vary depending on various factors, including the specific variant, an individual's health status, and the time since vaccination. Additionally, vaccine effectiveness can be influenced by factors such as the prevalence of the virus and the vaccination rate within a community.

It is worth noting that earlier studies, such as those conducted by the Centers for Disease Control and Prevention (CDC), reported higher effectiveness rates for the Moderna vaccine against hospitalisation. Some of these studies indicated effectiveness rates of around 93% for the Moderna vaccine. However, it is important to recognise that these studies were conducted at different times, with varying sample sizes, methodologies, and follow-up periods.

In conclusion, the Moderna vaccine's effectiveness against COVID-19-related hospitalisation is a dynamic and evolving area of research. While the recent study estimates 53% effectiveness, it adds to our understanding of the vaccine's protective capabilities. Ongoing surveillance and further studies are crucial to monitor the vaccine's effectiveness over time, especially as new variants emerge and vaccination coverage changes.

Moderna vaccine is most effective against hospitalisation, CDC study finds

A 2021 CDC-led study found that the Moderna vaccine is the most effective vaccine against COVID-19 hospitalisation. The study involved over 3,600 adults who were hospitalised at 21 hospitals across 18 states in the US between March and August 2021. Moderna's vaccine was found to be 93% effective in preventing hospitalisation, compared to 88% for the Pfizer vaccine and 71% for the Johnson & Johnson vaccine.

The Moderna vaccine's effectiveness against hospitalisation was also found to be more durable than that of the Pfizer vaccine. While Moderna's effectiveness remained at 93% beyond 120 days after inoculation, Pfizer's effectiveness fell to 77% during the same period. Researchers attributed the difference in effectiveness to several factors, including the higher mRNA content in the Moderna vaccine and the longer time between doses (four weeks for Moderna, compared to three for Pfizer).

The CDC study also compared antibody levels in the blood of healthy volunteers who had received one of the three available vaccines. Moderna recipients had the highest antibody levels, followed by Pfizer and then Johnson & Johnson. Despite the differences in effectiveness and antibody levels, the CDC emphasised that all three vaccines provide substantial protection against COVID-19 hospitalisation and serious illness.

In 2025, another study estimated the current Moderna vaccine to be 53% effective against COVID-19-related hospitalisation and 39% protective against medically attended COVID-19 over a median follow-up period of 57 days. This study, which has not yet been peer-reviewed, evaluated the effectiveness of Moderna's updated vaccine targeting the KP.2 variant.

Frequently asked questions